Every article on the Healio blog is researched and written by the Healio Editorial Team, the same small team that runs the store. This page explains how that work is done, what we will and will not publish, and how to tell us when we get something wrong.
Who writes the Healio blog
Articles carry the byline Healio Editorial Team. We do not publish under invented names, stock-photo authors or borrowed credentials. If a qualified outside reviewer checks an article in future, their name and qualification will appear on that article, and only on articles they actually reviewed.
How articles are researched
- Primary sources first. Claims are checked against the original record: PubMed abstracts, ClinicalTrials.gov study entries, FDA labels and DailyMed. Trial sizes, dates and approval status are confirmed at the source before a sentence goes live.
- Evidence is labeled for what it is. A result from a cell culture or an animal model is described as a cell or animal result. When a compound has no human trial evidence, the article says so plainly.
- Claims link to their source. Where a primary source can settle a claim, the article links to it so readers can check it themselves.
What we will not publish
- Dosing protocols, injection instructions or treatment schedules. The peptide calculator does concentration arithmetic on figures you enter and recommends nothing.
- Claims that any compound treats, cures or prevents a condition.
- Reviews, customer counts or “verified” badges we cannot back up.
All Healio products are sold for laboratory research use only. They are not intended for human consumption, and nothing on this site is medical advice.
How articles are updated and corrected
Each article shows the date it was last updated. We revisit articles when trial results, approvals or regulations change, and we correct errors when we find them. Recent examples:
- Five articles were updated after the retatrutide TRANSCEND-T2D-1 phase 3 trial completed in February 2026. They now say that individual phase 3 trials have finished, the program has not concluded, and no approval exists.
- An article that said thymosin beta-4 had no human trial evidence was corrected. The parent protein has reached small human trials; the TB-500 fragment has not.
- Our tirzepatide and semaglutide comparison now covers SURPASS-2, the head-to-head trial between the two.
If you spot an error, email support@healiopeptides.com with the page and the claim. We will check it against the source and fix it if we got it wrong.
Conflicts of interest
Healio sells many of the compounds we write about, and articles link to our products where they are relevant. Comparison articles that include Healio say so. Every batch we sell has its certificate of analysis published before you order, and the story behind Healio covers who we are.